

1/6

Cadena ligera de pembrolizumab

EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSL
EPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:5).

Cadena pesada de pembrolizumab

QVQLVQSGVEVKKPGASVKVCKASGYTFTNYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSS
TTTAYMELKSLQFDDTAVYYCARRDYRDMGFDYWGQTTTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
FLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVSVLTVLHQ
DWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:10).

FIG. 1

2/6




FIG.2

3/6




FIG.3A




FIG.3B

4/6




FIG.4A




FIG.4B

5/6




FIG. 5





FIG. 6



Abreviaciones: AA=acontecimiento adverso; ALK=Cinasa del linfoma anaplásico; ECOG=Grupo Cooperativo Oriental de Oncología; EGFR=receptor del factor de crecimiento epidérmico; IV=intravenoso; CPNM=cáncer de pulmón de células no pequeñas; PPT de PD-L1=puntuación de la proporción tumoral del ligando 1 de la muerte celular programada; c3sem.=cada 3 semanas; R=aleatoriedad; SC=subcutáneo; vs.=versus

FIG. 7